Journey Medical Corporation
Moat Score — Journey Medical Corporation
Total Moat Score
3 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 1 / 5 | Journey holds FDA approvals and some patent protection on newer products like Emrosi, but it does not develop its own chemistry and instead in-licenses assets, typically from affiliate Fortress Biotech, limiting the depth of proprietary intellectual property it controls outright. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | As a small specialty player with $61.9 million of FY2025 revenue, Journey has no scale-based manufacturing or distribution cost advantage versus much larger competitors such as Galderma and Almirall. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 1 / 5 | Emrosi's FDA approval and rapid payer-access expansion (100+ million covered lives within months of its April 2025 launch) support near-term branded pricing, but legacy products like Accutane and Targadox face generic erosion risk that limits durable pricing power across the portfolio. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Dermatology pharmaceutical sales exhibit no network effects; prescriber adoption of one Journey product does not make other products more valuable to additional prescribers or patients. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 0 / 5 | Dermatologists and patients can switch between branded and generic dermatology treatments with minimal friction, and payers can favor competing or generic products through formulary changes with little lock-in to Journey's portfolio. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | A dermatology-focused sales force reaching ~80% of dermatologists in the top 50 U.S. metro areas gives Journey a reasonably efficient niche footprint, but this is a modest scale advantage relative to much larger, broader-reach competitors. |